Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma

Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics.
Retrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021.
Overall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (n = 51) and in a subgroup of patients with murine double minute 2 (MDM2) amplification and wild-type tumor protein p53 (TP53 WT) (n = 38, 74.5%). Patients had a median age of 64.8 years, and 62.7% were male. The most common first-line treatment was doxorubicin with olaratumab (23.5%). From time of first-line (1 L) treatment, median OS for the entire cohort and MDM2-amplified, TP53 WT subgroup was 12.6 and 11.7 months, respectively; median rwPFS was 2.5 months for both. Median TTNT was 3.9 months for the full cohort and 4.8 months for the MDM2-amplified, TP53 WT subgroup.
The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options.
Researchers have been looking into a rare and aggressive cancer called dedifferentiated liposarcoma (DDLPS) to better understand how it’s treated, what genetic markers are involved, and how patients fare with current treatments. They studied medical records covering the years 2011–2021 from a large US database, focusing on patients who received treatment for DDLPS that had spread to other parts of the body. The study included 51 patients, with a significant portion having a specific genetic feature (murine double minute 2 [MDM2] gene amplification) and a normal version of another gene (wild-type tumor protein p53 [TP53 WT]). Most patients were around 65 years old and predominantly male. The most common initial treatment was a combination of doxorubicin and olaratumab. The researchers found that patients lived about 12.6 months after starting treatment, with survival being slightly shorter, about 11.7 months, for those having the specific genetic feature. Patients typically did not see their cancer progress for about 2.5 months, and it took around 3.9–4.8 months before they needed a new treatment. This study helps fill in some gaps about DDLPS by showing what treatments are being used and how patients are doing, which could help in designing future clinical trials for new treatments.